PMID- 23628094
OWN - NLM
STAT- MEDLINE
DCOM- 20140205
LR  - 20130430
IS  - 1166-7087 (Print)
IS  - 1166-7087 (Linking)
VI  - 23
IP  - 6
DP  - 2013 May
TI  - [Prostate brachytherapy: indications and outcomes].
PG  - 378-85
LID - S1166-7087(12)00697-5 [pii]
LID - 10.1016/j.purol.2012.12.006 [doi]
AB  - INTRODUCTION: To summarize the indications and outcomes of low dose-rate prostate 
      brachytherapy with permanent implants. METHODS: Bibliographic database PubMed was 
      searched with prostate cancer and brachytherapy as keywords from 1995 to 2012. 
      RESULTS: The main indication of prostate brachytherapy is the favorable group, 
      but it could be proposed to patients with an intermediate prognostic group if the 
      PSA is </= 15 ng/mL or if the Gleason score is 7 (3+4), under cover of a prostate 
      MRI without any extra-capsular extension. Oncologic results are similar to those 
      of surgery or external beam irradiation (EBRT), with a 10-yr biochemical control 
      rate approaching 90%. Urinary toxicity is common during the year following the 
      implant, mainly irritative symptoms; 5 to 15% of patients experienced acute 
      urinary retention. A prostate volume higher than 50 cc or an initial high 
      international prostatic symptom score (IPSS) are predictive of toxicity and are 
      recognized as relative contraindications of the technique. Sexual activity is 
      maintained in 60% of patients. CONCLUSION: Brachytherapy must be proposed as a 
      validated option beside active surveillance, surgery and EBRT.
CI  - Copyright (c) 2013 Elsevier Masson SAS. All rights reserved.
FAU - Hennequin, C
AU  - Hennequin C
AD  - Service de cancerologie radiotherapie, hopital Saint-Louis, AP-HP, 1, avenue 
      Claude-Vellefeaux, 75475 Paris, France. christophe.hennequin@sls.aphp.fr
FAU - Cormier, L
AU  - Cormier L
FAU - Richaud, P
AU  - Richaud P
FAU - Bastide, C
AU  - Bastide C
FAU - Beuzeboc, P
AU  - Beuzeboc P
FAU - Fromont, G
AU  - Fromont G
FAU - Mongiat-Artus, P
AU  - Mongiat-Artus P
FAU - Peyromaure, M
AU  - Peyromaure M
FAU - Ploussard, G
AU  - Ploussard G
FAU - Renard-Penna, R
AU  - Renard-Penna R
FAU - Rozet, F
AU  - Rozet F
FAU - Soulie, M
AU  - Soulie M
FAU - Salomon, L
AU  - Salomon L
CN  - Les membres du CC-AFU
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Curietherapie exclusive du cancer de la prostate par implants permanents : 
      indications et resultats. Revue du CC-AFU.
DEP - 20130129
PL  - France
TA  - Prog Urol
JT  - Progres en urologie : journal de l'Association francaise d'urologie et de la 
      Societe francaise d'urologie
JID - 9307844
SB  - IM
MH  - *Brachytherapy/adverse effects
MH  - Humans
MH  - Male
MH  - Prostatic Neoplasms/*radiotherapy
MH  - Treatment Outcome
EDAT- 2013/05/01 06:00
MHDA- 2014/02/06 06:00
CRDT- 2013/05/01 06:00
PHST- 2012/12/02 00:00 [received]
PHST- 2012/12/12 00:00 [revised]
PHST- 2012/12/14 00:00 [accepted]
PHST- 2013/05/01 06:00 [entrez]
PHST- 2013/05/01 06:00 [pubmed]
PHST- 2014/02/06 06:00 [medline]
AID - S1166-7087(12)00697-5 [pii]
AID - 10.1016/j.purol.2012.12.006 [doi]
PST - ppublish
SO  - Prog Urol. 2013 May;23(6):378-85. doi: 10.1016/j.purol.2012.12.006. Epub 2013 Jan 
      29.